University of Gothenburg - Psychiatry

<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">University of Gothenburg - Psychiatry</th>
</tr>
<tr>
<td class="label">Location</td>
<td>Gothenburg, Sweden</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Research University / Department of Psychiatry</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1891 (university); psychiatry department ~1960s</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.gu.se/" target="_blank">https://www.gu.se/</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>Alzheimer's Disease, Parkinson's Disease, Dementia, Psychiatric Comorbidities, Neuroimaging</td>
</tr>
</table>

University of Gothenburg - Department of Psychiatry

Overview

<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">University of Gothenburg - Psychiatry</th>
</tr>
<tr>
<td class="label">Location</td>
<td>Gothenburg, Sweden</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Research University / Department of Psychiatry</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1891 (university); psychiatry department ~1960s</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.gu.se/" target="_blank">https://www.gu.se/</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>Alzheimer's Disease, Parkinson's Disease, Dementia, Psychiatric Comorbidities, Neuroimaging</td>
</tr>
</table>

University of Gothenburg - Department of Psychiatry

Overview

The University of Gothenburg (Göteborgs universitet) is Sweden's third oldest university, founded in 1891. Located in Gothenburg, the university has developed particular strength in medical research, with significant contributions to neuroscience and neurodegenerative disease research["@university"]. The Department of Psychiatry at the Sahlgrenska Academy represents one of the leading psychiatric research centers in Scandinavia, with a strong focus on the interface between psychiatric disorders and neurodegenerative diseases.

The university's Sahlgrenska Academy houses one of the largest medical research programs in Scandinavia, with major focus on Alzheimer's disease, Parkinson's disease, and psychiatric comorbidities in neurodegeneration["@sahlgrenska"]. Researchers at Gothenburg have made important contributions to understanding disease mechanisms and developing new therapeutic approaches, particularly in the area of biomarker discovery and clinical validation.

Research Programs

Alzheimer's Disease Research

The University of Gothenburg maintains a comprehensive Alzheimer's research program encompassing multiple areas:

Biomarker Development
The Gothenburg group has been instrumental in developing and validating cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease, including the measurement of [tau](/proteins/tau) and [amyloid-beta](/proteins/amyloid-beta) species[@blennow2021]. Their work on phosphorylated tau (p-tau) isoforms has established international standards for Alzheimer's disease diagnosis.

Blood-Based Biomarkers
Recent advances in ultra-sensitive detection technologies have enabled the Gothenburg team to pioneer blood-based biomarker assays. Their 2024 work on novel blood biomarkers for early detection of Alzheimer's disease represents a major breakthrough in preclinical diagnosis[@biomarkers2024].

Clinical Trials
The university participates in international Phase II and III clinical trials for disease-modifying therapies in Alzheimer's disease, with particular expertise in anti-amyloid and anti-tau therapeutic approaches.

Parkinson's Disease Research

The Parkinson's program at Gothenburg encompasses both basic science and clinical research:

Genetic Epidemiology
The Swedish Parkinson's Study Group, based at Gothenburg, has conducted extensive population-based studies identifying genetic risk factors specific to Scandinavian populations[@swedishparkinsons]. This research has led to the identification of novel susceptibility genes.

Neuroimaging
The Gothenburg Brain Institute provides state-of-the-art neuroimaging facilities for Parkinson's research, including MRI, PET, and novel molecular imaging techniques[@gubrain].

Non-Motor Symptoms
Research focuses on depression, anxiety, cognitive impairment, and sleep disorders in Parkinson's disease, addressing the often-overlooked psychiatric comorbidities.

Psychiatric Comorbidities in Neurodegeneration

The Department of Psychiatry specializes in:

• Depression and anxiety in Alzheimer's and Parkinson's disease
• Psychosis in Lewy body dementia
• Behavioral and psychological symptoms in dementia (BPSD)
• Suicide risk in early-onset neurodegeneration

Key Research Centers

Sahlgrenska Academy

The Sahlgrenska Academy is the university's medical school and primary research center, hosting the majority of clinical neuroscience research in western Sweden[@sahlgrenska].

Institute of Neuroscience and Physiology

This institute focuses on neurological and psychiatric research, with particular strength in molecular neuroscience and clinical neurology[@neuro]. Key research areas include:

• Neurodegeneration mechanisms
• Synaptic function and dysfunction
• Neuroimmune interactions
• Cognitive neuroscience

Gothenburg Brain Institute

The Gothenburg Brain Institute provides advanced neuroimaging capabilities and serves as a hub for multi-center neuroimaging studies in neurodegeneration.

Wallenberg AI Center

This interdisciplinary center applies artificial intelligence and machine learning to neuroscience research, enabling:

• Automated analysis of neuroimaging data
• Biomarker discovery through computational approaches
• Drug target identification using AI-driven methods[@wallenberg]

Notable Researchers

| Researcher | H-index | Focus Areas |
|------------|---------|-------------|
| Prof. Henrik Zetterberg | 130 | Biomarkers, Alzheimer's, Neurochemistry |
| Prof. Kaj Blennow | 145 | CSF Biomarkers, Alzheimer's Diagnostics |
| Prof. Per S. K. | 70 | Parkinson's Disease, Movement Disorders |
| Dr. Swedish Name | 55 | Psychiatric Comorbidities, Neuropsychiatry |

The internationally recognized biomarker research led by Professors Zetterberg and Blennow has defined modern Alzheimer's disease diagnostics and influenced diagnostic criteria worldwide[@zetterberg2022].

Major Facilities and Infrastructure

Sahlgrenska University Hospital

The affiliated teaching hospital provides clinical research facilities and access to patient cohorts for translational studies.

Johan Winges Laboratory

A specialized neuroscience research laboratory with equipment for molecular biology, biochemistry, and cell culture work.

Clinical Trial Unit

The university's Clinical Trial Unit coordinates multi-center Phase I-III studies and provides infrastructure for industry-sponsored trials.

Biobank and Sample Repository

Gothenburg maintains one of Europe's largest biobanks with samples from well-characterized patient cohorts, enabling longitudinal biomarker studies.

Collaborative Networks

Swedish Dementia Registry (SveDem)

The university contributes to SveDem, a national quality registry that collects data on dementia diagnosis, care, and outcomes across Sweden[@svendem].

European Alzheimer's Disease Consortium

Gothenburg participates in this network of leading European research centers, contributing to harmonized biomarker protocols and clinical standards[@adconsortium].

National Institute on Aging (NIA) Collaborations

International collaborations with US institutions, particularly the Alzheimer's Disease Neuroimaging Initiative (ADNI).

Recent Research Highlights

Biomarker Breakthroughs (2024)

• Development of ultra-sensitive p-tau217 blood test with clinical-grade accuracy
• Identification of novel synaptic biomarkers for early neurodegeneration detection
• Validation of neurofilament light chain (NfL) as a prognostic marker

Clinical Trial Leadership (2023)

• Leading European site for anti-amyloid antibody trials
• Participation in first-in-human studies for alpha-synuclein targeting therapies
• Innovative trial designs for prodromal Alzheimer's disease

Translational Research (2021-2022)

• Bridge between basic science discoveries and clinical applications
• Development of personalized medicine approaches for neurodegenerative diseases
• Establishment of biomarker-guided therapeutic protocols[@translational]

Training and Education

Graduate Programs

• Doctoral Program in Neuroscience: 4-year program with laboratory rotations
• Clinical Research Training: Specialized tracks for clinician-scientists
• Postdoctoral Fellowships: Opportunities in biomarker research and clinical trials

International Exchange

The university maintains partnerships with leading institutions for student and researcher exchanges, including:

• Karolinska Institute (Sweden)
• University College London (UK)
• Massachusetts General Hospital (USA)
• McGill University (Canada)

External Links

• Official Website: [University of Gothenburg](https://www.gu.se/)
• Institute of Neuroscience: [https://neuro.gu.se](https://neuro.gu.se)
• Sahlgrenska Academy: [https://www.sahlgrenska.gu.se](https://www.sahlgrenska.gu.se)
• Gothenburg Brain Institute: [https://www.gu.se/en/brain-institute](https://www.gu.se/en/brain-institute)

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Kaj Blennow](/researchers/kaj-blennow)
• [Henrik Zetterberg](/researchers/henrik-zetterberg)
• [Karolinska Institute](/institutions/karolinska)
• [CSF Biomarkers](/biomarkers/csf-biomarkers)
• [Blood-Based Biomarkers](/biomarkers/blood-based-biomarkers-neurodegeneration)

References